ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION
LOE Approachingfexofenadine hydrochloride and pseudoephedrine hydrochloride
NDAORALTABLET, EXTENDED RELEASE
Approved
Oct 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION (fexofenadine hydrochloride and pseudoephedrine hydrochloride) by Sanofi. Approved for these symptoms due to hay fever, other upper respiratory allergies: ▪ runny nose ▪ sneezing ▪ itchy, watery eyes ▪ itching of the nose and 4 more indications. First approved in 2004.
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALLEGRA-D 24 HOUR is a fixed-dose combination oral tablet combining fexofenadine hydrochloride (a non-sedating antihistamine) and pseudoephedrine hydrochloride (a nasal decongestant). It treats symptoms of hay fever and upper respiratory allergies including runny nose, sneezing, itchy/watery eyes, and nasal congestion, with 24-hour symptom relief and extended-release delivery.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30), indicating team focus is likely on lifecycle management and transition strategy rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.